---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-020713"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T05:52:10.546975+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roivant Q4 net loss widens to $206.5M; brepocitinib DM readout on track for H2 2025

## Summary
- Net loss attributable to Roivant of $206.5M ($0.29 loss per share) for Q4 FY2025, vs $151.1M loss ($0.19) a year ago.
- Revenue of $7.6M, down 16% YoY; R&D expenses rose 35% to $145.2M.
- Consolidated cash, equivalents, restricted cash and marketable securities of $4.9B at March 31, 2025.
- Repurchased $1.3B of shares, reducing outstanding shares by 14% from March 31, 2024.
- Brepocitinib Phase 3 in dermatomyositis fully enrolled; topline data expected H2 2025; NIU Phase 3 enrolling.

## SEC filing metadata
- accession: 0001140361-25-020713
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/0001140361-25-020713-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125020713/ef20049462_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-020713
- JSON: https://secwatch.observer/filing/0001140361-25-020713.json
- Plain text: https://secwatch.observer/filing/0001140361-25-020713.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.